At a glance
| Compound type | Peptidomimetic research compound |
|---|---|
| Proposed pathway | HGF/c-Met; not clinically validated |
| Material evidence change | Two foundational papers retracted in 2025 |
| Human efficacy | Not established |
| Human safety | Not adequately characterized |
Overview
Dihexa was developed in research on angiotensin-IV-derived compounds and proposed modifiers of hepatocyte growth factor signaling. It is commonly grouped with peptides, although a chemically modified peptidomimetic is a more precise description. The central issue is evidence integrity: published results can no longer be treated as dependable support once the relevant papers are retracted. This does not prove that every possible biological effect is absent, but it removes a basis for confidently claiming enhanced cognition or neuronal repair. The sources checked did not identify a reliable human clinical program establishing cognitive benefit or an adequately characterized safety profile.
How it works
The proposed mechanism involved enhancement of hepatocyte growth factor/c-Met signaling and downstream synaptic effects. The 2014 paper directly connecting procognitive and synaptogenic effects to that pathway was retracted, as was a 2012 precursor paper on angiotensin-IV analogs as HGF/Met modifiers. Consequently, this mechanism should be labeled an unconfirmed historical hypothesis requiring reliable independent replication, not a validated therapeutic explanation.
What was retracted
The journal published retraction notices for the 2012 paper on angiotensin-IV analogs as HGF/Met modifiers and the 2014 paper on HGF/c-Met-dependent procognitive and synaptogenic effects. A retraction is not simply a request for more research. The affected results should no longer be used as reliable affirmative evidence for treatment claims.
What can and cannot be concluded
The notices identify an important problem in the evidentiary foundation. They do not themselves measure the efficacy or toxicity of Dihexa in humans. A responsible account therefore avoids both declaring a demonstrated benefit and inventing a measured clinical harm. Independent, reproducible experiments would be needed before rebuilding the mechanistic case.
Why commercial availability does not resolve uncertainty
FDA reports that it has not identified human exposure data for drug products containing Dihexa acetate and cannot adequately characterize the associated risks. Commercial availability does not supply that missing evidence. Claims of reliable brain penetration, durable cognitive benefit, or predictable long-term safety therefore remain unsupported by an established human clinical program.
Supporting sources [3]
Frequently asked questions
Does a retraction prove that Dihexa has no biological effects?
No. It means the affected publications should not be used as reliable evidence. The biological question would need sound independent research.
Can older synapse or cognition claims still be called established?
No. The 2025 notices withdraw important support for that narrative. Reliable human efficacy and safety evidence would still be needed even if a mechanism were independently reproduced.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Experimental angiotensin-IV-derived peptidomimetic.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Retraction notice: Development of Angiotensin IV Analogs as HGF/Met Modifiers ↗Original research · Checked 2026-10-27
- Retraction notice: Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides ↗Original research · Checked 2026-10-27
- FDA: safety concerns for certain bulk substances proposed for compounding ↗Regulatory source · Checked 2026-10-27